Moreover, targeted CPT1 therapy reduces the formation of invasive pseudopodia in hepatocellular cancer cells and eliminates the tumor-promoting effect of tumor-associated macrophages (TAMs) (Su et al., 2020). The gene discussed is CPT2; the disease is neoplasm.